Table 4.
Univariate analysis of the prognostic value of miR-125b-5p expression levels in relation to relapse-free survival in different hormone receptor–positive breast cancers a
| Number of samples | Univariate analysis | |||
|---|---|---|---|---|
| Hazard ratio | 95% CI | P -value b | ||
| All breast tumor samples | 65 | 6.80 | 1.35 to 35.26 | 0.009 |
| HR+/HER2− subclass | 30 | 4.81 | N/A | 0.03 |
| Luminal A subclass (HR+, HER2−, SBR1 or SBR2)c | 19 | 3.75 | N/A | 0.05 |
| Luminal B subclass (HR+, HER2+ and/or SBR3)c | 17 | 1.69 | 0.07 to 17.12 | 0.96 |
a95% CI, 95% confidence interval; HER2, Human epidermal growth factor receptor 2; HR+, Hormone receptor–positive (estrogen receptor (ER) and/or progesterone receptor (PR)); miR, MicroRNA; N/A, Not applicable as there is no relapse event in the low miR-125b-5p expression level group; SBR, Scarff-Bloom-Richardson grade. b P < 0.05 was considered significant. cSubclasses of breast cancer were determined using immunohistological (ER, PR, HER2) and SBR grades according to the St Gallen recommendation [38].